(Reuters) – Takeda Pharmaceutical said on Tuesday it would acquire Nimbus Therapeutics’ experimental inflammatory disease treatment for $4 billion in upfront payment.
(Reporting by Khushi Mandowara; Editing by Vinay Dwivedi)
Takeda to buy inflammatory disease drug for $4 billion from Nimbus
Dec 13, 2022 | 7:37 AM
